Akoya Biosciences Inc (AKYA)

$2.46

+0.02

(+0.82%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.43
    $2.50
    $2.46
    downward going graph

    1.22%

    Downside

    Day's Volatility :2.8%

    Upside

    1.6%

    downward going graph
  • $1.88
    $7.06
    $2.46
    downward going graph

    23.58%

    Downside

    52 Weeks Volatility :73.37%

    Upside

    65.16%

    downward going graph

Returns

PeriodAkoya Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-35.79%
6.5%
0.0%
6 Months
-49.69%
7.1%
0.0%
1 Year
-64.99%
9.8%
0.0%
3 Years
-85.61%
14.2%
-20.2%

Highlights

Market Capitalization
122.0M
Book Value
$0.66
Earnings Per Share (EPS)
-1.42
Wall Street Target Price
6.0
Profit Margin
-72.68%
Operating Margin TTM
-92.85%
Return On Assets TTM
-22.59%
Return On Equity TTM
-181.72%
Revenue TTM
93.6M
Revenue Per Share TTM
1.99
Quarterly Revenue Growth YOY
-14.299999999999999%
Gross Profit TTM
43.4M
EBITDA
-47.0M
Diluted Eps TTM
-1.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.05
EPS Estimate Next Year
-0.65
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Akoya Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 143.9%

Current $2.46
Target $6.00

Company Financials

FY19Y/Y Change
Revenue
42.2M
-
Net Income
-14.8M
-
Net Profit Margin
-34.93%
-
FY20Y/Y Change
Revenue
42.4M
↑ 0.49%
Net Income
-16.7M
↑ 13.25%
Net Profit Margin
-39.36%
↓ 4.43%
FY21Y/Y Change
Revenue
54.9M
↑ 29.39%
Net Income
-42.9M
↑ 157.0%
Net Profit Margin
-78.18%
↓ 38.82%
FY22Y/Y Change
Revenue
74.9M
↑ 36.31%
Net Income
-70.6M
↑ 64.53%
Net Profit Margin
-94.37%
↓ 16.19%
FY23Y/Y Change
Revenue
96.6M
↑ 29.09%
Net Income
-63.3M
↓ 10.36%
Net Profit Margin
-65.53%
↑ 28.84%
Q4 FY22Q/Q Change
Revenue
21.2M
↑ 12.56%
Net Income
-18.9M
↑ 5.61%
Net Profit Margin
-88.95%
↑ 5.85%
Q1 FY23Q/Q Change
Revenue
21.4M
↑ 0.9%
Net Income
-18.8M
↓ 0.39%
Net Profit Margin
-87.82%
↑ 1.13%
Q2 FY23Q/Q Change
Revenue
23.5M
↑ 9.86%
Net Income
-20.8M
↑ 10.64%
Net Profit Margin
-88.44%
↓ 0.62%
Q3 FY23Q/Q Change
Revenue
25.2M
↑ 7.2%
Net Income
-12.9M
↓ 37.91%
Net Profit Margin
-51.22%
↑ 37.22%
Q4 FY23Q/Q Change
Revenue
26.5M
↑ 5.04%
Net Income
-10.8M
↓ 16.37%
Net Profit Margin
-40.78%
↑ 10.44%
Q1 FY24Q/Q Change
Revenue
18.4M
↓ 30.72%
Net Income
-23.5M
↑ 117.4%
Net Profit Margin
-127.98%
↓ 87.2%
FY19Y/Y Change
Total Assets
89.4M
-
Total Liabilities
119.6M
-
FY20Y/Y Change
Total Assets
77.7M
↓ 13.14%
Total Liabilities
59.1M
↓ 50.58%
FY21Y/Y Change
Total Assets
190.9M
↑ 145.82%
Total Liabilities
69.6M
↑ 17.71%
FY22Y/Y Change
Total Assets
176.0M
↓ 7.79%
Total Liabilities
117.5M
↑ 68.86%
FY23Y/Y Change
Total Assets
180.4M
↑ 2.46%
Total Liabilities
126.6M
↑ 7.79%
Q4 FY22Q/Q Change
Total Assets
176.0M
↓ 0.24%
Total Liabilities
117.5M
↑ 15.86%
Q1 FY23Q/Q Change
Total Assets
154.3M
↓ 12.35%
Total Liabilities
112.2M
↓ 4.49%
Q2 FY23Q/Q Change
Total Assets
188.9M
↑ 22.41%
Total Liabilities
117.0M
↑ 4.28%
Q3 FY23Q/Q Change
Total Assets
177.2M
↓ 6.16%
Total Liabilities
115.3M
↓ 1.46%
Q4 FY23Q/Q Change
Total Assets
180.4M
↑ 1.76%
Total Liabilities
126.6M
↑ 9.83%
Q1 FY24Q/Q Change
Total Assets
154.8M
↓ 14.2%
Total Liabilities
122.0M
↓ 3.61%
FY19Y/Y Change
Operating Cash Flow
-13.8M
-
Investing Cash Flow
-12.9M
-
Financing Cash Flow
28.6M
-
FY20Y/Y Change
Operating Cash Flow
-6.8M
↓ 50.33%
Investing Cash Flow
6.7M
↓ 152.19%
Financing Cash Flow
5.5M
↓ 80.79%
FY21Y/Y Change
Operating Cash Flow
-36.1M
↑ 427.08%
Investing Cash Flow
-5.1M
↓ 175.71%
Financing Cash Flow
137.0M
↑ 2397.9%
FY22Y/Y Change
Operating Cash Flow
-53.5M
↑ 48.32%
Investing Cash Flow
-14.1M
↑ 176.38%
Financing Cash Flow
28.7M
↓ 79.04%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.0M
↓ 17.78%
Investing Cash Flow
22.1M
↑ 204.58%
Financing Cash Flow
10.3M
↑ 4.16%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.8M
↑ 97.44%
Investing Cash Flow
6.2M
↓ 72.0%
Financing Cash Flow
-419.0K
↓ 104.08%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.8M
↓ 40.26%
Investing Cash Flow
-1.4M
↓ 122.97%
Financing Cash Flow
46.3M
↓ 11156.56%

Technicals Summary

Sell

Neutral

Buy

Akoya Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akoya Biosciences Inc
Akoya Biosciences Inc
-5.43%
-49.69%
-64.99%
-85.61%
-90.63%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-1.32%
16.54%
32.6%
35.62%
148.32%
Resmed Inc.
Resmed Inc.
11.69%
9.57%
-6.0%
-19.79%
64.22%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.5%
-1.64%
-17.69%
-6.68%
-8.49%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-14.37%
-23.3%
-26.95%
-26.58%
102.44%
Alcon Ag
Alcon Ag
2.41%
20.84%
8.21%
30.7%
54.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akoya Biosciences Inc
Akoya Biosciences Inc
NA
NA
NA
-1.05
-1.82
-0.23
NA
0.66
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
78.14
78.14
7.13
6.63
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
32.24
32.24
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
50.71
50.71
1.34
13.04
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.71
42.71
6.72
7.74
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
44.05
44.05
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akoya Biosciences Inc
Akoya Biosciences Inc
Buy
$122.0M
-90.63%
NA
-72.68%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$161.3B
148.32%
78.14
27.65%
Resmed Inc.
Resmed Inc.
Buy
$30.8B
64.22%
32.24
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$68.6B
-8.49%
50.71
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$23.7B
102.44%
42.71
19.42%
Alcon Ag
Alcon Ag
Buy
$45.8B
54.72%
44.05
10.96%

Insights on Akoya Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 26.48M → 18.35M (in $), with an average decrease of 30.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -10.80M → -23.48M (in $), with an average decrease of 117.4% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 32.6% return, outperforming this stock by 97.6%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 35.6% return, outperforming this stock by 121.2%

Institutional Holdings

  • Blue Water Life Science Advisors, LLC

    9.51%

  • Polar Capital Holdings PLC

    3.20%

  • Vanguard Group Inc

    2.94%

  • BlackRock Inc

    2.73%

  • Parkman Healthcare Partners LLC

    1.86%

  • Uniplan Investment Counsel, Inc.

    1.42%

Company Information

akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling.​..all on your existing microscope​. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.

Organization
Akoya Biosciences Inc
Employees
330
CEO
Mr. Brian McKelligon
Industry
Healthcare

Discover More

FAQs